Fund manager
Baker Brothers Investments
Baker Brothers Investments · Biotech
Quarter ending 30 Jun 2026 · Filed 14 Aug 2026 · 83 positions · $19.9B reported
Investor focused on biotechnology and life sciences. Added from a public list of the largest hedge fund managers.
Top holdings
| Company | Weight | Value (13F) |
|---|---|---|
| Incyte Corporation (INCY) | 17.5% | $3.5B |
| Beone Medicines Ltd. (ONC) | 12.6% | $2.5B |
| Revolution Medicines, Inc. (RVMD) | 10.8% | $2.1B |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 5.8% | $1.2B |
| Acadia Pharmaceuticals Inc. (ACAD) | 5.5% | $1.1B |
| Kymera Therapeutics, Inc. (KYMR) | 5.0% | $992.7M |
| Insmed Incorporated (INSM) | 4.7% | $937.8M |
| Celcuity Inc. (CELC) | 4.2% | $828.2M |
| Kodiak Sciences Inc. (KOD) | 3.9% | $776.1M |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 3.1% | $622.3M |
| Praxis Precision Medicines, Inc. (PRAX) | 3.0% | $587.0M |
| Alkermes Plc | 2.6% | $524.6M |
| Summit Therapeutics Inc. (SMMT) | 2.4% | $477.7M |
| Grail, Inc. (GRAL) | 1.4% | $275.0M |
| Abcellera Biologics Inc. (ABCL) | 1.3% | $259.1M |
Source: Form 13F-HR filing on SEC EDGAR (accession 0001104659-26-097191), for the quarter ending 30 Jun 2026, filed 14 Aug 2026. A 13F lists long US-listed equity positions only, filed up to 45 days after quarter end, so it is a look back, not a live portfolio. Values are as reported in the filing.
Open the interactive profile: buys and sells, track record, mimic portfolio